ERK signaling pathway may induce gemcitabine chemoresistance in pancreatic cancer cell line SW1990 by regulating the expression of mdr-1 and RRM1 gene

Chinese-German Journal of Clinical Oncology

Volumn 8, Issue 1, 2009, Pages

  Chen, Denglin ^a   Xie, Derong ^a   Guo, Shuangshuang ^b   Yang, Qiong ^a   Jiang, Zhimin ^a   Bi, Zhuofei ^a   Ma, Wen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Drug resistance; Extracellular signal regulated kinase (ERK) pathway; Gemcitabine(GEM); Pancreatic neoplasm

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA ACTIN; EPIDERMAL GROWTH FACTOR; GEMCITABINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL GROWTH; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 59149097840     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-008-0145-5     Document Type: Article

References (19)

1. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: Is the glass less empty? Oncologist, 2008, 13: 562-576.
2. Yao J, Feng FY, Lin C, et al. The mechanism of resistance to 2′,2prime;-difluorodeoxyxytidine (gemcitabine) in a pancreatic cancer cell line. Chin J Oncol (Chinese), 2005, 27: 721-726.
3. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer, 2007, 120: 1355-1363.
4. Lu Z, Kleeff J, Shrikhande S, et al. Expression of the multidrug-resistance 1 (mdr1) gene and prognosis in human pancreatic cancer. Pancreas, 2000, 21: 240-247.
5. Messersmith WA, Hidalgo M, Carducci M, et al. Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol, 2006, 4: 831-836.
6. Niu BZ, Chen G, Li LJ, et al. Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cell strain SW1990 induced by gemcitabine. Acta Acad Med Sin (Chinese), 2005, 27: 606-610.
7. Germann UA, Pastan I, Gottesman MM. P-glycoproteins: Mediators of multidrug resistance. Semin Cell Biol, 1993, 4: 63-76.
8. Kim SO, Jeong JY, Kim MR, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res, 2008, 14: 3083-3088.
9. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004, 10: 1318-1325.
10. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res, 2004, 10: 4215-4219.
11. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer, 2007, 96: 457-463.
12. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004, 64: 3761-3766.
13. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002, 298: 1911-1912.
14. Guan J, Chen XP, Zhu H, et al. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol, 2004, 10: 3522-3527.
15. Chen B, Jin F, Lu P, et al. Effect of mitogen-activated protein kinase signal transduction pathway on multidrug resistance induced by vincristine in gastric cancer cell line MGC803. World J Gastroenterol, 2004, 10: 795-799.
16. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase. J Biol Chem, 1998, 273: 18623-18632.
17. Zhao Y, Shen S, Guo J, et al. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res, 2006, 136: 325-355.
18. Li Z, Liu CP, He YL. The expression and significance of multi-drug resistance genes in breast cancer. Chinese-German J Clin Oncol, 2008, 7: 538-541.
19. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol, 2007, 608: 23-30.